Cathie Wood's ARK Invest Sells Over 185,000 Shares of Roche

Investing

Published: August 23, 2021 7:45 am

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 185,000 shares of Swiss multinational health care company Roche on Friday, as the share price of the fund traded up over 1% in the day’s session. Its share price has greatly improved over the past year.

ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 189,500 over-the-counter shares of Roche. At Friday’s closing price, this would have valued this sale at roughly $9.5 million. This is only a small fraction of the total holdings. This fund is up 29% over the past 52 weeks.

Here is a quick look at all the other sales that took place across all ARK ETFs:

Fund	Ticker	Company Name	Shares Traded
ARKF	1833HK	Ping An Good Doctor	1,951,500
ARKG	PSTI	Pluristem Therapeutics	4,301
ARKG	CDNA	CareDx	73,873
ARKG	RHHBY	Roche	189,500
ARKK	PRLB	Proto Labs	17,225
ARKK	SQ	Square	43,266
ARKK	SE	Sea	66,115
ARKQ	XONE	Exone	91,224
ARKQ	BIDU	Baidu	84,975
ARKW	MELI	Mercado	5,185
ARKW	SQ	Square	36,059

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.

24/7 Wall St.
This Analyst Loves 4 BDC Stocks to Buy Now Paying Huge, Dependable Dividends

Are You Ahead, or Behind on Retirement? (sponsor)

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention.

Finding a financial advisor who puts your interest first can be the difference between a rich retirement and barely getting by, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors that serve your area in minutes. Each advisor has been carefully vetted, and must act in your best interests. Start your search now.

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.